Develops innovative therapies for genetic disorders and other diseases, focusing on recombinant proteins.
Pharming Group N.V., based in Leiden, the Netherlands, is a prominent biopharmaceutical company dedicated to advancing protein replacement therapies and precision medicines worldwide. Established with a focus on addressing rare diseases and unmet medical needs, Pharming Group N.V. has positioned itself at the forefront of innovation in healthcare. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor specifically developed for the treatment of acute hereditary angioedema, providing critical relief to patients.
Pharming Group N.V. is actively involved in the development of several promising therapies. This includes rhC1INH for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is advancing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor for patients with activated PI3K delta syndrome, and exploring alpha-glucosidase therapy for the treatment of Pompe and Fabry diseases. Pharming Group N.V. has established strategic collaborations to bolster its research and development efforts, including a partnership with Novartis and a collaboration with Orchard Therapeutics plc, focusing on the investigational gene therapy OTL-105 for hereditary angioedema.
Driven by a commitment to scientific excellence and patient-centric care, Pharming Group N.V. continues to expand its portfolio of transformative therapies. Through strategic partnerships, rigorous clinical trials, and a global approach to healthcare innovation, the company strives to make meaningful advancements in treating rare diseases, improving outcomes, and enhancing the quality of life for patients worldwide.